{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:42:17Z","timestamp":1790743337043,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1124\/dmd.118.084905","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T01:12:24Z","timestamp":1542330744000},"page":"135-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017"],"prefix":"10.1016","volume":"47","author":[{"given":"Jingjing","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiko D.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ragueneau-Majlessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.084905_bib1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2125.2010.03845.x","article-title":"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects","volume":"71","author":"Abbas","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.084905_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13318-014-0235-4","article-title":"CYP3A4-based drug-drug interaction: CYP3A4 substrates\u2019 pharmacokinetic properties and ketoconazole dose regimen effect","volume":"41","author":"Boulenc","year":"2016","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.118.084905_bib3","first-page":"47","article-title":"Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general","volume":"2","author":"Boxenbaum","year":"1999","journal-title":"J Pharm Pharm Sci"},{"key":"10.1124\/dmd.118.084905_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1177391X0700100001","article-title":"Lead optimization in discovery drug metabolism and pharmacokinetics\/case study: the hepatitis C virus (HCV) protease inhibitor SCH 503034","volume":"1","author":"Cheng","year":"2007","journal-title":"Perspect Medicin Chem"},{"key":"10.1124\/dmd.118.084905_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1517\/17425255.1.4.641","article-title":"Functional interactions between P-glycoprotein and CYP3A in drug metabolism","volume":"1","author":"Christians","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.118.084905_bib6","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","article-title":"Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers","volume":"72","author":"Dutreix","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.118.084905_bib7","unstructured":"Food and Drug Administration (FDA) (2012) Guidance for industry: drug interaction studies\u2014study sesign, data analysis, and implications for dosing and labeling recommendations (draft guidance), Center for Drug Evaluation and Research., FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib8","unstructured":"Food and Drug Administration (FDA) (2017a) Guidance for industry: clinical drug interaction studies\u2014study design, data analysis, and clinical implications for dosing and labeling recommendations (draft guidance), Center for Drug Evaluation and Research., FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib9","unstructured":"Food and Drug Administration (FDA) (2017b) Guidance for industry: in vitro metabolism- and transporter-mediated drug-drug interaction studies (draft guidance). Center for Drug Evaluation and Research., FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib10","series-title":"Drug Approval Package: ALUNBRIG (Brigatinib). FDA Application NDA 208772","year":"2017"},{"key":"10.1124\/dmd.118.084905_bib11","series-title":"Drug Approval Package: AUSTEDO (Deutetrabenazine). FDA Application NDA 208082","year":"2017"},{"key":"10.1124\/dmd.118.084905_bib12","series-title":"Drug Approval Package: BEVYXXA (Betrixaban). FDA Application NDA 208383","year":"2017"},{"key":"10.1124\/dmd.118.084905_bib13","series-title":"Drug Approval Package: CALQUENCE (Acalabrutinib). FDA Application NDA 210259","year":"2017"},{"key":"10.1124\/dmd.118.084905_bib14","series-title":"Drug Approval Package: EMFLAZA (Deflazacort). FDA Application NDA 208684","year":"2017"},{"key":"10.1124\/dmd.118.084905_bib15","unstructured":"Food and Drug Administration (FDA) (2017h) Drug Approval Package: INGREZZA (Valbenazine). FDA Application NDA 209241, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib16","unstructured":"Food and Drug Administration (FDA) (2017i) Drug Approval Package: KISQALI (Ribociclib Succinate). FDA Application NDA 209092, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib17","unstructured":"Food and Drug Administration (FDA) (2017j) Drug Approval Package: MAVYRET (Glecaprevir and Pibrentasvir). FDA Application NDA 209394, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib18","unstructured":"Food and Drug Administration (FDA) (2017k) Drug Approval Package: NERLYNX (Neratinib Maleate). FDA Application NDA 208051, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib19","unstructured":"Food and Drug Administration FDA (2017l) Drug Approval Package: PREVYMIS (Letermovir). FDA Application NDA 209939, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib20","unstructured":"Food and Drug Administration FDA (2017m) Drug Approval Package: RYDAPT (Midostaurin). FDA Application NDA 207997, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib21","unstructured":"Food and Drug Administration FDA (2017n) Drug Approval Package: STEGLATRO (Ertugliflozin). FDA Application NDA 209803, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib22","unstructured":"Food and Drug Administration FDA (2017o) Drug Approval Package: SYMPROIC (Naldemedine Tosylate). FDA Application NDA 208854, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib23","unstructured":"Food and Drug Administration FDA (2017p) Drug Approval Package: VERZENIO (Abemaciclib). FDA Application NDA 208716, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib24","unstructured":"Food and Drug Administration FDA (2017q) Drug Approval Package: VOSEVI (Sofosbuvir, Velpatasvir, and Voxilaprevir). FDA Application NDA 209195, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib25","unstructured":"Food and Drug Administration (FDA (2017r) Drug Approval Package: XADAGO (Safinamide). FDA Application NDA 207145, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib26","unstructured":"Food and Drug Administration (FDA) (2017s) Drug Approval Package: XERMELO (Telotristat Ethyl). FDA Application NDA 208794, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib27","unstructured":"Food and Drug Administration (FDA) (2018) Guidance for industry: physiologically based pharmacokinetic analyses\u2014format and content, Center for Drug Evaluation and Research, FDA, Silver Spring, MD."},{"key":"10.1124\/dmd.118.084905_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/0091270005284854","article-title":"Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin","volume":"46","author":"Gurley","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.118.084905_bib29","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.118.084905_bib30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2003.02041.x","article-title":"Database analyses for the prediction of in vivo drug-drug interactions from in vitro data","volume":"57","author":"Ito","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.084905_bib31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40262-015-0334-7","article-title":"Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir","volume":"55","author":"Mogalian","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.118.084905_bib32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.084905_bib33","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1124\/dmd.114.060392","article-title":"Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review","volume":"42","author":"Yu","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.084905_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/dmd.115.066720","article-title":"Key findings from preclinical and clinical drug interaction studies presented in new drug and biological license applications approved by the Food and Drug Administration in 2014","volume":"44","author":"Yu","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.084905_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/dmd.116.073411","article-title":"What can be learned from recent new drug applications? A systematic review of drug interaction data for drugs approved by the US FDA in 2015","volume":"45","author":"Yu","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.084905_bib36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1124\/dmd.117.078691","article-title":"Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016","volume":"46","author":"Yu","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.084905_bib37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr Drug Metab"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624077456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624077456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.084905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T13:51:25Z","timestamp":1739886685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624077456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0090955624077456"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.084905","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.084905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}